There is increasing concern regarding the volume of opioid medications prescribed postoperatively, and the rate of prescription opioid related adverse-events. However, data regarding patient 0 s postoperative opioids needs following surgery for pelvic organ prolapse are sparse. To better understand and potentially improve opioid stewardship in women undergoing prolapse surgery in our practice, we evaluated patient 0 s actual postoperative requirements and implemented procedurespecific opioid prescribing recommendations based on these findings. We then evaluated the impact of these changes on opioid prescribing, use, pain control, and patient satisfaction.
INTRODUCTION AND OBJECTIVES:
There is increasing concern regarding the volume of opioid medications prescribed postoperatively, and the rate of prescription opioid related adverse-events. However, data regarding patient 0 s postoperative opioids needs following surgery for pelvic organ prolapse are sparse. To better understand and potentially improve opioid stewardship in women undergoing prolapse surgery in our practice, we evaluated patient 0 s actual postoperative requirements and implemented procedurespecific opioid prescribing recommendations based on these findings. We then evaluated the impact of these changes on opioid prescribing, use, pain control, and patient satisfaction.
METHODS: We prospectively evaluated opioid prescribing patterns, patient utilization, medication refills, and patient satisfaction in women undergoing prolapse surgery (i.e. vaginal, abdominal, or robotic) during an eight-month time-period. Two cohorts of women, stratified by whether they had surgery before or after implementation of procedurespecific tiered opioid prescribing recommendations, were evaluated. Postoperative opioid usage (assessed via pill count) and satisfaction with pain management after hospital dismissal were evaluated by telephone call two weeks after surgery. Postoperative opioid prescribing and use were recorded after conversion to Oral Morphine Equivalents (OME).
RESULTS: Overall, 96 women were included, 57 in the initial baseline cohort, and 39 following implementation of the prescribing recommendations. In the initial cohort, 3607/11007 mg (32.8%) of the prescribed OME were consumed. Following implementation of the prescribing recommendations, median OME prescribed decreased from 200 mg OME (IQR 150,225) to 112.5 mg OME (IQR 22.5,112.5; p <0.0001). The total OME prescribed decreased by 45% when compared with the volume that would have been prescribed before implementing the recommendations. The amount of leftover opioids per patient significantly decreased as well (p<0.0001). Pain medication refills increased after the intervention (18% vs 3.5%; p[0.03), while satisfaction scores were similar in both cohorts (p[0.87).
CONCLUSIONS: At baseline, overprescribing of opioids following pelvic organ prolapse surgery was common. By utilizing procedure-specific opioid prescribing recommendations we decreased the number of opioids prescribed at hospital dismissal by roughly half. The aim of our study was evaluate efficiency and safety transvaginal repair of anterior and apical prolapse using OPUR 6-strap mesh.
METHODS: The study included 110 patients with urogenital prolapse: grade 3-4 cystocele and grade 2-4 hysteroptosis. The average age was 59 years. The maximum follow up was 5 years. Quality of life and sexual function were assessed with PFDI-20, PFIQ-7 and PSIQ-12 questionnaires.
The main advantage of 6-strap meshes over their 4-strap predecessors is two additional straps designed for the correction of hysteroptosis and prevention of mesh shrinkage. These straps are introduced through the sacrospinal and underlying sacroiliac ligaments with the stylet inserted in-out under full manual control after preliminary ligament dissection and dislocation of the rectum medially. Apart from that, the transversal vaginal wall incision -through which the mesh is introduced -is located at the isthmus level. This allows for separation of the wound and mesh.
RESULTS: We achieved the desired result in 107 (97%) cases (Stage I, POP-Q System). No patients developed postoperative dyspareunia. Quality of life improved in 106 patients (96%) according to PFDI-20 and in 107 cases (97%) according to PFIQ-7. Questionnaire scores were the same at 3 and 12 months after surgery. Ten patients had stress urinary incontinence prior to surgery. In 5 of them, it resolved postoperatively. Eight patients (7%) developed de novo incontinence that required mediurethral sling placement in 4 cases. At 3 months after surgery, the women reported less emotional stress during communication and sexual intercourse. The complications were as follows: 12 hematomas in the anterior wall of the vagina that resolved without treatment, acute ischuria in 10 cases that resolved within 3-7 days and two erosions that required excision of the mesh fragment. In one 40-year-old patient, we noted injury of the urinary bladder that was managed intraoperatively with transvaginal sacrospinous hysteropexy. The treatment was completed using one sacrospinal strap from the opposite side fixed to the isthmus with subsequent anterior colporrhaphy.
CONCLUSIONS: Transvaginal reconstructive surgery for anterior and apical urogenital prolapse using a 6-strap mesh may be considered effective and relatively safe. It offered good short-and long-term anatomical and functional outcomes.
